Keryx Biopharmaceuticals (KERX) Shares are Up 1.14%

Keryx Biopharmaceuticals (KERX) : Traders are bullish on Keryx Biopharmaceuticals (KERX) as it has outperformed the S&P 500 by a wide margin of 28.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.98%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.14% in the last 1 week, and is up 27.95% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 12.44% and the 50-Day Moving Average is 7.22%.The 200 Day SMA reached 5.93%


Keryx Biopharmaceuticals (NASDAQ:KERX): After opening at $5.15, the stock dipped to an intraday low of $5.09 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.44 and the buying power remained strong till the end. The stock closed at $5.31 for the day, a gain of 3.11% for the day session. The total traded volume was 1,535,424. The stocks close on the previous trading day was $5.31.

Keryx Biopharmaceuticals (KERX) : Currently there are 4 street experts covering Keryx Biopharmaceuticals (KERX) stock. The most bullish and bearish price target for the stock is $9 and $4 respectively for the short term. The average price target of all the analysts comes to $6.75. The estimated standard deviation from the target is $2.06.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.